Identification

Name
Clevidipine
Accession Number
DB04920
Type
Small Molecule
Groups
Approved, Investigational
Description

Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.

Structure
Thumb
Synonyms
  • Clevidipine butyrate
External IDs
H-324/38
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CleviprexEmulsion0.5 mgIntravenousChiesi Farmaceutici S.P.A.Not applicableNot applicableCanada
CleviprexEmulsion.5 mg/mLIntravenousChiesi Pharmaceuticals Inc.2008-09-15Not applicableUs
CleviprexEmulsion.5 mg/mLIntravenousFresenius Kabi Austria Gmb H2008-09-15Not applicableUs
CleviprexEmulsion.5 mg/mLIntravenousChiesi Pharmaceuticals Inc.2008-09-15Not applicableUs
CleviprexEmulsion.5 mg/mLIntravenousThe Medicines Company2008-09-15Not applicableUs
CleviprexEmulsion.5 mg/mLIntravenousChiesi Pharmaceuticals Inc.2008-09-15Not applicableUs
Categories
UNII
19O2GP3B7Q
CAS number
167221-71-8
Weight
Average: 456.316
Monoisotopic: 455.090242887
Chemical Formula
C21H23Cl2NO6
InChI Key
KPBZROQVTHLCDU-UHFFFAOYSA-N
InChI
InChI=1S/C21H23Cl2NO6/c1-5-7-15(25)29-10-30-21(27)17-12(3)24-11(2)16(20(26)28-4)18(17)13-8-6-9-14(22)19(13)23/h6,8-9,18,24H,5,7,10H2,1-4H3
IUPAC Name
methyl 5-{[(butanoyloxy)methoxy]carbonyl}-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylate
SMILES
CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC

Pharmacology

Indication

For the treatment of hypertension.

Associated Conditions
Pharmacodynamics

Clevidipine belongs to a well-known class of drugs called dihydropyridine calcium channel antagonists. Clevidpine is the first third generation intravenous dihydropyridine calcium channel blocker. In vitro studies demonstrated that clevidipine acts by selectively relaxing the smooth muscle cells that line small arteries, resulting in arterial dilation, widening of the artery opening, and without reducing central venous pressure or reducing cardiac output.

Mechanism of action

Possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, clevidipine inhibits the influx of extracellular calcium across both the myocardial and vascular smooth muscle cell membranes. The resultant inhibition of the contractile processes of the myocardial smooth muscle cells leads to dilation of the coronary and systemic arteries and improved oxygen delivery to the myocardial tissue.

TargetActionsOrganism
UVoltage-dependent L-type calcium channel subunit alpha-1FNot AvailableHuman
UVoltage-dependent L-type calcium channel subunit alpha-1SNot AvailableHuman
UVoltage-dependent L-type calcium channel subunit alpha-1DNot AvailableHuman
UVoltage-dependent L-type calcium channel subunit alpha-1CNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

>99.5%

Metabolism

Clevidipine is rapidly hydrolyzed to inactive metabolites by esterases in arterial blood.

Route of elimination

urine 63-74%, feces 7-22%

Half life

1 minute

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Clevidipine.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Clevidipine.Vet Approved
AbirateroneThe serum concentration of Clevidipine can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Clevidipine.Approved, Investigational
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Clevidipine.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Clevidipine.Approved
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Clevidipine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Clevidipine is combined with Aliskiren.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Clevidipine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Clevidipine.Approved
AmiodaroneThe metabolism of Clevidipine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Clevidipine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Clevidipine.Approved
AmobarbitalThe metabolism of Clevidipine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Clevidipine.Approved, Investigational
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Clevidipine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Clevidipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Clevidipine.Approved
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Clevidipine.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Clevidipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Clevidipine.Approved
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Clevidipine.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Clevidipine.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Clevidipine.Approved, Investigational
ArtemetherThe metabolism of Clevidipine can be decreased when combined with Artemether.Approved
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Clevidipine.Approved
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Clevidipine.Approved, Investigational, Withdrawn
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Clevidipine.Approved
AtomoxetineThe metabolism of Clevidipine can be decreased when combined with Atomoxetine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Clevidipine is combined with Azilsartan medoxomil.Approved, Investigational
AzithromycinThe metabolism of Clevidipine can be decreased when combined with Azithromycin.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Clevidipine.Experimental
BarbexacloneThe metabolism of Clevidipine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Clevidipine can be increased when combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Clevidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Clevidipine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Clevidipine.Approved
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Clevidipine.Approved, Investigational
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Clevidipine.Approved, Withdrawn
BetaxololThe metabolism of Clevidipine can be decreased when combined with Betaxolol.Approved, Investigational
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Clevidipine.Approved
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Clevidipine.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Clevidipine.Approved
BortezomibThe metabolism of Clevidipine can be decreased when combined with Bortezomib.Approved, Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Clevidipine.Experimental
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Clevidipine.Approved
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Clevidipine.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Clevidipine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clevidipine.Approved, Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Clevidipine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Clevidipine.Approved
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Clevidipine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clevidipine.Approved, Investigational
BupropionThe metabolism of Clevidipine can be decreased when combined with Bupropion.Approved
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Clevidipine.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Clevidipine.Approved
CaffeineThe metabolism of Clevidipine can be decreased when combined with Caffeine.Approved
Calcium AcetateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Phosphate.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Clevidipine.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Clevidipine.Withdrawn
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Clevidipine.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Clevidipine.Approved
CarbamazepineThe metabolism of Clevidipine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Clevidipine.Approved, Investigational
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Clevidipine.Approved
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Clevidipine.Approved, Investigational
CaseinThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Clevidipine.Approved
CelecoxibThe metabolism of Clevidipine can be decreased when combined with Celecoxib.Approved, Investigational
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Clevidipine.Approved
ChloroquineThe metabolism of Clevidipine can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Clevidipine.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Clevidipine.Approved
ChlorpromazineThe metabolism of Clevidipine can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Clevidipine.Approved
CholecalciferolThe metabolism of Clevidipine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Clevidipine.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Clevidipine.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Clevidipine.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Clevidipine.Approved, Investigational
CimetidineThe serum concentration of Clevidipine can be increased when it is combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Clevidipine can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Clevidipine can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Clevidipine can be decreased when combined with Clemastine.Approved, Investigational
ClobazamThe metabolism of Clevidipine can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Clevidipine.Approved, Investigational
ClomipramineThe metabolism of Clevidipine can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Clevidipine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Clevidipine.Approved
ClotrimazoleThe metabolism of Clevidipine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clevidipine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Clevidipine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Clevidipine can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Clevidipine.Approved, Investigational
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Clevidipine.Investigational
CurcuminThe metabolism of Clevidipine can be decreased when combined with Curcumin.Approved, Investigational
CyclosporineThe metabolism of Clevidipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Clevidipine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Clevidipine.Approved
DarifenacinThe metabolism of Clevidipine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Clevidipine can be increased when it is combined with Darunavir.Approved
DeferasiroxThe serum concentration of Clevidipine can be increased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Clevidipine can be decreased when combined with Delavirdine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Clevidipine.Approved
DesipramineThe metabolism of Clevidipine can be decreased when combined with Desipramine.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clevidipine.Approved, Vet Approved
DextroamphetamineThe risk or severity of hypotension can be increased when Dextroamphetamine is combined with Clevidipine.Approved, Illicit
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Clevidipine.Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Clevidipine.Approved, Investigational
DiltiazemClevidipine may increase the hypotensive activities of Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Clevidipine is combined with Dinutuximab.Approved, Investigational
DiphenhydramineThe metabolism of Clevidipine can be decreased when combined with Diphenhydramine.Approved, Investigational
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Clevidipine.Approved
DosulepinThe metabolism of Clevidipine can be decreased when combined with Dosulepin.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Clevidipine.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Clevidipine.Approved, Investigational
DronedaroneThe metabolism of Clevidipine can be decreased when combined with Dronedarone.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Clevidipine.Approved, Vet Approved
DuloxetineClevidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Clevidipine.Approved
EfavirenzThe serum concentration of Clevidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Clevidipine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Clevidipine.Approved, Investigational
EliglustatThe metabolism of Clevidipine can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Clevidipine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Clevidipine.Approved
EpinephrineThe risk or severity of hypotension can be increased when Epinephrine is combined with Clevidipine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Clevidipine.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Clevidipine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Clevidipine.Approved
EscitalopramThe risk or severity of hypotension can be increased when Escitalopram is combined with Clevidipine.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Clevidipine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Clevidipine.Approved, Investigational
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Clevidipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Clevidipine.Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Clevidipine.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Clevidipine.Approved, Investigational
FluconazoleThe serum concentration of Clevidipine can be increased when it is combined with Fluconazole.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Clevidipine.Approved, Investigational
FluoxetineThe metabolism of Clevidipine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Clevidipine.Approved, Investigational, Withdrawn
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Clevidipine.Experimental
FluvoxamineThe metabolism of Clevidipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Clevidipine.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Clevidipine.Approved, Vet Approved
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Clevidipine.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Clevidipine.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Clevidipine.Approved, Investigational
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Clevidipine.Experimental
HaloperidolThe metabolism of Clevidipine can be decreased when combined with Haloperidol.Approved
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Clevidipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Clevidipine.Approved, Vet Approved
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Clevidipine.Approved, Investigational
HexobarbitalThe metabolism of Clevidipine can be increased when combined with Hexobarbital.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Clevidipine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Clevidipine.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Clevidipine.Approved, Investigational
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Clevidipine.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Clevidipine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Clevidipine.Investigational
ImipramineThe metabolism of Clevidipine can be decreased when combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Clevidipine.Approved
IndinavirThe metabolism of Clevidipine can be decreased when combined with Indinavir.Approved
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Clevidipine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Clevidipine.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Clevidipine.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Clevidipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Clevidipine.Approved, Vet Approved
IsoniazidThe metabolism of Clevidipine can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Clevidipine.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Clevidipine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Clevidipine.Approved, Investigational
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Clevidipine.Approved, Investigational
KetoconazoleThe metabolism of Clevidipine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Clevidipine.Approved
LacidipineClevidipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Clevidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Clevidipine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Clevidipine.Approved, Investigational
LevodopaClevidipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Clevidipine.Approved, Investigational
LidocaineThe metabolism of Clevidipine can be decreased when combined with Lidocaine.Approved, Vet Approved
LisdexamfetamineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Clevidipine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Clevidipine.Approved, Investigational
LobeglitazoneThe metabolism of Clevidipine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Clevidipine.Approved, Investigational
LopinavirThe metabolism of Clevidipine can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Clevidipine can be decreased when combined with Lorcaserin.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Clevidipine.Approved
LumefantrineThe metabolism of Clevidipine can be decreased when combined with Lumefantrine.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Clevidipine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Clevidipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Clevidipine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Clevidipine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Clevidipine can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Clevidipine.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Clevidipine.Approved, Investigational
MelatoninMelatonin may decrease the antihypertensive activities of Clevidipine.Approved, Nutraceutical, Vet Approved
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Clevidipine.Experimental
MethadoneThe metabolism of Clevidipine can be decreased when combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Clevidipine.Approved
MethohexitalThe metabolism of Clevidipine can be increased when combined with Methohexital.Approved
MethotrimeprazineThe metabolism of Clevidipine can be decreased when combined with Methotrimeprazine.Approved, Investigational
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Clevidipine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Clevidipine.Approved
MethylphenobarbitalThe metabolism of Clevidipine can be increased when combined with Methylphenobarbital.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Clevidipine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Clevidipine.Approved
MetoprololThe metabolism of Clevidipine can be decreased when combined with Metoprolol.Approved, Investigational
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Clevidipine.Experimental
MexiletineThe metabolism of Clevidipine can be decreased when combined with Mexiletine.Approved, Investigational
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Clevidipine.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Clevidipine.Approved, Investigational, Vet Approved
MidostaurinThe metabolism of Clevidipine can be decreased when combined with Midostaurin.Approved, Investigational
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Clevidipine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Clevidipine.Approved, Investigational
MirabegronThe metabolism of Clevidipine can be decreased when combined with Mirabegron.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Clevidipine.Approved
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Clevidipine.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Clevidipine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Clevidipine.Approved, Investigational
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Clevidipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Clevidipine.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Clevidipine.Approved
NafcillinThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Clevidipine.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Clevidipine.Approved
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Clevidipine.Approved, Investigational
NefazodoneThe risk or severity of hypotension can be increased when Nefazodone is combined with Clevidipine.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Clevidipine.Approved, Investigational
NevirapineThe metabolism of Clevidipine can be decreased when combined with Nevirapine.Approved
NicardipineThe metabolism of Clevidipine can be decreased when combined with Nicardipine.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Clevidipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Clevidipine.Approved, Investigational
NicotineThe metabolism of Clevidipine can be decreased when combined with Nicotine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Clevidipine.Approved
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Clevidipine.Experimental
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Clevidipine.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Clevidipine.Investigational
NilotinibThe metabolism of Clevidipine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Clevidipine.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Clevidipine.Approved, Investigational
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Clevidipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Clevidipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Clevidipine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Clevidipine.Approved, Investigational
NitroprussideClevidipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Clevidipine.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Clevidipine.Approved
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Clevidipine.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Clevidipine.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Clevidipine.Approved, Investigational
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Clevidipine.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Clevidipine.Approved, Investigational
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Clevidipine.Experimental
OsimertinibThe serum concentration of Clevidipine can be decreased when it is combined with Osimertinib.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Clevidipine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clevidipine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Clevidipine.Approved, Vet Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Clevidipine.Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Clevidipine.Approved
PanobinostatThe serum concentration of Clevidipine can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Clevidipine.Approved, Investigational
ParoxetineThe metabolism of Clevidipine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Clevidipine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Clevidipine.Approved, Investigational
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Clevidipine.Approved, Investigational
PentobarbitalThe metabolism of Clevidipine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Clevidipine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Clevidipine.Approved
PhenobarbitalThe metabolism of Clevidipine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Clevidipine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Clevidipine.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Clevidipine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clevidipine.Approved, Investigational
PitolisantThe metabolism of Clevidipine can be decreased when combined with Pitolisant.Approved, Investigational
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Clevidipine.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Clevidipine.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Clevidipine.Approved, Investigational
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Clevidipine.Approved
PrimidoneThe metabolism of Clevidipine can be increased when combined with Primidone.Approved, Vet Approved
PromazineThe metabolism of Clevidipine can be decreased when combined with Promazine.Approved, Vet Approved
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Clevidipine.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Clevidipine.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Clevidipine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Clevidipine.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Clevidipine.Approved, Investigational
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Clevidipine.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clevidipine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Clevidipine.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Clevidipine.Approved, Investigational
QuinineThe metabolism of Clevidipine can be decreased when combined with Quinine.Approved
RacepinephrineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Clevidipine.Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Clevidipine.Experimental
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Clevidipine.Approved
RanolazineThe metabolism of Clevidipine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Clevidipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clevidipine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clevidipine.Approved, Investigational
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Clevidipine.Approved, Investigational
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Clevidipine.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Clevidipine.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Clevidipine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Clevidipine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Clevidipine is combined with Riociguat.Approved
RisperidoneClevidipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Clevidipine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Clevidipine can be decreased when combined with Rolapitant.Approved, Investigational
RopiniroleThe metabolism of Clevidipine can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clevidipine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Clevidipine.Approved
RucaparibThe metabolism of Clevidipine can be decreased when combined with Rucaparib.Approved, Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Clevidipine.Approved
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Clevidipine.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Clevidipine.Approved, Investigational, Vet Approved
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Clevidipine.Approved
SecobarbitalThe metabolism of Clevidipine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Clevidipine.Approved, Investigational, Vet Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Clevidipine.Approved, Investigational
SertralineThe metabolism of Clevidipine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clevidipine.Approved, Vet Approved
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Clevidipine.Approved
SimeprevirThe metabolism of Clevidipine can be decreased when combined with Simeprevir.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Clevidipine.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Clevidipine.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Clevidipine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Clevidipine.Approved
StiripentolThe metabolism of Clevidipine can be decreased when combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Clevidipine.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clevidipine.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Clevidipine.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Clevidipine.Approved, Investigational
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Clevidipine.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Clevidipine.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Clevidipine.Approved, Investigational
Tenofovir disoproxilThe metabolism of Clevidipine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Clevidipine.Approved
TerbinafineThe metabolism of Clevidipine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Clevidipine.Approved
TeriflunomideThe serum concentration of Clevidipine can be decreased when it is combined with Teriflunomide.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Clevidipine.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Clevidipine can be decreased when combined with Theophylline.Approved
ThiamylalThe metabolism of Clevidipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Clevidipine can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Clevidipine.Approved
ThioridazineThe metabolism of Clevidipine can be decreased when combined with Thioridazine.Approved, Withdrawn
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Clevidipine.Approved
TiclopidineThe metabolism of Clevidipine can be decreased when combined with Ticlopidine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Clevidipine.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Clevidipine.Approved
TipranavirThe metabolism of Clevidipine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Clevidipine.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Clevidipine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clevidipine.Approved, Withdrawn
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Clevidipine.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Clevidipine.Approved, Investigational, Vet Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Clevidipine.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Clevidipine.Approved
TranylcypromineThe metabolism of Clevidipine can be decreased when combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Clevidipine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Clevidipine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Clevidipine.Approved
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Clevidipine.Approved, Investigational
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Clevidipine.Experimental
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Clevidipine.Approved, Investigational
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Clevidipine.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Clevidipine.Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Clevidipine.Approved, Investigational
VemurafenibThe serum concentration of Clevidipine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Clevidipine can be decreased when combined with Venlafaxine.Approved
VerapamilClevidipine may increase the hypotensive activities of Verapamil.Approved
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Clevidipine.Approved, Investigational
WortmanninThe therapeutic efficacy of Wortmannin can be increased when used in combination with Clevidipine.Experimental
ZiprasidoneThe metabolism of Clevidipine can be decreased when combined with Ziprasidone.Approved
ZucapsaicinThe metabolism of Clevidipine can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Clevidipine.Approved, Investigational
Food Interactions
  • Grapefruit Juice

References

General References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008]
  2. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770]
  3. Wang QD, Segawa D, Ericsson H, Sjoquist PO, Johansson L, Ryden L: Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I. J Cardiovasc Pharmacol. 2002 Aug;40(2):228-34. [PubMed:12131552]
  4. Stephens CT, Jandhyala BS: Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats. Clin Exp Hypertens. 2002 May;24(4):301-13. [PubMed:12069360]
External Links
KEGG Drug
D08892
PubChem Compound
153994
PubChem Substance
175426904
ChemSpider
135722
ChEBI
135738
ChEMBL
CHEMBL1237132
Wikipedia
Clevidipine
ATC Codes
C08CA16 — Clevidipine
AHFS Codes
  • 24:28.08 — Dihydropyridines
FDA label
Download (381 KB)
MSDS
Download (568 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHigh Blood Pressure (Hypertension)1
2Unknown StatusTreatmentCerebral Aneurysms / Subarachnoid Hemorrhage / Vasospasm, Intracranial1
2Unknown StatusTreatmentHigh Blood Pressure (Hypertension) / Subarachnoid Hemorrhage1
2, 3CompletedTreatmentNeuromuscular Scoliosis1
3CompletedTreatmentHeart Failure, Unspecified / High Blood Pressure (Hypertension)1
3CompletedTreatmentHemorrhage / High Blood Pressure (Hypertension)1
3CompletedTreatmentHigh Blood Pressure (Hypertension)6
4CompletedDiagnosticPulmonary Hypertension (PH)1
4CompletedTreatmentEpilepsies / High Blood Pressure (Hypertension) / Neoplasms, Brain1
4RecruitingTreatmentNontraumatic Intracerebral Hemorrhage, Multiple Localized1
4TerminatedTreatmentAortic Aneurysms / Aortic Diseases1
4Unknown StatusTreatmentPediatric Perioperative Blood Pressure Management1
4WithdrawnTreatmentHigh Blood Pressure (Hypertension)2
4WithdrawnTreatmentHigh Blood Pressure (Hypertension) / Intracranial Hemorrhages / Subarachnoid Hemorrhage1
Not AvailableWithdrawnTreatmentAorta Aneurysm / Dissection of Aorta1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
EmulsionIntravenous.5 mg/mL
EmulsionIntravenous0.5 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5739152No1995-04-142015-04-14Us
US5856346No2001-01-052021-01-05Us
US8658676No2011-10-102031-10-10Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00267 mg/mLALOGPS
logP4.98ALOGPS
logP4.09ChemAxon
logS-5.2ALOGPS
pKa (Strongest Basic)5.31ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area90.93 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity113.93 m3·mol-1ChemAxon
Polarizability45.12 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9887
Blood Brain Barrier-0.5892
Caco-2 permeable+0.6566
P-glycoprotein substrateSubstrate0.5787
P-glycoprotein inhibitor IInhibitor0.8948
P-glycoprotein inhibitor IINon-inhibitor0.6827
Renal organic cation transporterNon-inhibitor0.8312
CYP450 2C9 substrateNon-substrate0.8879
CYP450 2D6 substrateNon-substrate0.8693
CYP450 3A4 substrateSubstrate0.693
CYP450 1A2 substrateInhibitor0.6871
CYP450 2C9 inhibitorInhibitor0.6818
CYP450 2D6 inhibitorNon-inhibitor0.8455
CYP450 2C19 inhibitorInhibitor0.7456
CYP450 3A4 inhibitorInhibitor0.9187
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9098
Ames testNon AMES toxic0.7527
CarcinogenicityNon-carcinogens0.8407
BiodegradationNot ready biodegradable0.9403
Rat acute toxicity2.6248 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7841
hERG inhibition (predictor II)Non-inhibitor0.8148
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0059-0015900000-5d813bb035601f752e65
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000l-0019000000-3e3b6549a7821bc27951

Taxonomy

Description
This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Hydropyridines
Direct Parent
Dihydropyridinecarboxylic acids and derivatives
Alternative Parents
Tricarboxylic acids and derivatives / Dichlorobenzenes / Acylals / Fatty acid esters / Aryl chlorides / Vinylogous amides / Methyl esters / Enoate esters / Amino acids and derivatives / Acetals
show 8 more
Substituents
Dihydropyridinecarboxylic acid derivative / Tricarboxylic acid or derivatives / 1,2-dichlorobenzene / Chlorobenzene / Acylal / Fatty acid ester / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1F
Uniprot ID
O60840
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1F
Molecular Weight
220675.9 Da
References
  1. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1S
Uniprot ID
Q13698
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight
212348.1 Da
References
  1. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1D
Uniprot ID
Q01668
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight
245138.75 Da
References
  1. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Ericsson H, Tholander B, Regardh CG: In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci. 1999 Apr;8(1):29-37. [PubMed:10072476]

Drug created on October 21, 2007 16:23 / Updated on July 13, 2018 01:09